Table 3.
Treatment responses
| Regimen | Time to progression (months) |
Response (3 months) |
Response (6 months) |
Status | Death from stopping regimen (months) |
Follow-up (months) |
|
|---|---|---|---|---|---|---|---|
| Patient | |||||||
| 1 | BIT | 6 | SD | PD | Dead | 2 | |
| 2 | BIT | 14 | PR | CR | AWDa | N/A | 20 |
| 3 | BIT | N/A | PR | PR | AWD PF | N/A | 15 |
| 4 | BIT | 11 | PR | CR | Dead | 2 | |
| 5 | BI | 6 | PR | PD | Dead | 4 | |
| 6 | BIT | N/A | SD | SD | AWD PF | N/A | 55 |
| 7 | BI | 18 | PR | CR | Dead | 3 | |
| 8 | BITV | 10 | PR | PR | Dead | 3 | |
| 9 | BITV | 4 | SD | PD | Dead | 2 |
Bl bevacizumab+irinotecan, BIT BI+temozolomide, BITV BIT+vincristine, N/A not applicable, AWD alive with disease, CR complete response, PD progressive disease, PF progression free, PR partial response, SD stable disease
a
Progressed after 14 months of salvage therapy, but remains AWD for 18 months